Literature DB >> 18521020

Update on the pattern electroretinogram in glaucoma.

Michael Bach1, Michael B Hoffmann.   

Abstract

PURPOSE: To review the efficacy of the pattern electroretinogram (PERG) in early diagnosis of glaucoma.
METHODS: Stimulation parameters of check size and temporal frequency are considered. Analyses of various peaks (P50, N95, the N95/P50) and Fourier steady-state are considered. The relation to visual field defects is explored.
RESULTS: The PERG is markedly alterated in glaucoma. It shows amplitude reductions in (still) normal areas of the visual field. Optical imaging on the retina needs to be optimal. Higher temporal frequency (>10 reversals/s) improves the sensitivity to detect glaucoma compared with transient stimulation. The ratio between the amplitudes to 0.8 degrees checks and to 16 degrees checks, "PERG ratio," exploits a check size-specific reduction in early glaucoma and reduces variability. Longitudinal studies suggest that the PERG can indicate incipient glaucoma damage before evidence from the visual field.
CONCLUSIONS: The PERG is a demanding electrophysiological technique that can serve as a sensitive biomarker for retinal ganglion cell function. With appropriate paradigms, PERG assists in identifying those patients with elevated interocular pressure in whom glaucoma damage is incipient before visual field changes occur.

Entities:  

Mesh:

Year:  2008        PMID: 18521020     DOI: 10.1097/OPX.0b013e318177ebf3

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  60 in total

1.  Pattern electroretinogram progression in glaucoma suspects.

Authors:  Lori M Ventura; Iuri Golubev; William J Feuer; Vittorio Porciatti
Journal:  J Glaucoma       Date:  2013-03       Impact factor: 2.503

2.  Progressive loss of retinal ganglion cell function is hindered with IOP-lowering treatment in early glaucoma.

Authors:  Lori M Ventura; William J Feuer; Vittorio Porciatti
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

3.  Head-down posture induces PERG alterations in early glaucoma.

Authors:  Lori M Ventura; Iuri Golubev; William Lee; Izuru Nose; Jean-Marie Parel; William J Feuer; Vittorio Porciatti
Journal:  J Glaucoma       Date:  2013-03       Impact factor: 2.503

4.  On- and off-response ERGs elicited by sawtooth stimuli in normal subjects and glaucoma patients.

Authors:  Gobinda Pangeni; Robert Lämmer; Ralf P Tornow; Folkert K Horn; Jan Kremers
Journal:  Doc Ophthalmol       Date:  2012-03-29       Impact factor: 2.379

5.  Retinal pathway origins of the pattern electroretinogram (PERG).

Authors:  Xunda Luo; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-01       Impact factor: 4.799

6.  The photopic negative response of the flash electroretinogram in multiple sclerosis.

Authors:  Jing Wang; Han Cheng; Ying-Sheng Hu; Rosa A Tang; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

Review 7.  Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.

Authors:  S D Crish; D J Calkins
Journal:  Neuroscience       Date:  2010-12-25       Impact factor: 3.590

Review 8.  [Functional glaucoma diagnosis].

Authors:  C Erb; K Göbel
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

9.  Comparison of human expert and computer-automated systems using magnitude-squared coherence (MSC) and bootstrap distribution statistics for the interpretation of pattern electroretinograms (PERGs) in infants with optic nerve hypoplasia (ONH).

Authors:  Anthony C Fisher; Daphne L McCulloch; Mark S Borchert; Pamela Garcia-Filion; Cassandra Fink; Antonio Eleuteri; David M Simpson
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

10.  Adaptation of the steady-state PERG in early glaucoma.

Authors:  Vittorio Porciatti; Brandon Bosse; Prashant K Parekh; Olga A Shif; William J Feuer; Lori M Ventura
Journal:  J Glaucoma       Date:  2014 Oct-Nov       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.